PROK FY2026 earnings: results, stock reaction and implied move

Reported results

Cash, cash equivalents and marketable securities totaled $142M as of September 30, 2026.
Total Class A and Class B shares outstanding were 302,381,712 as of November 6, 2026.
Analyst coverage stood at 7 firms.
No rilparencel-related serious adverse events were observed across 49 patients in the REGEN-007 study.

Current cash is expected to fund operating plans into mid-2027.
Full enrollment for the Phase 3 PROACT 1 study is anticipated in Q1 2027 with over 500 patients expected to be enrolled.
Topline readout for the Phase 3 PROACT 1 surrogate endpoint (eGFR slope) is anticipated in Q2 2027 with an efficacy analysis set of approximately 320 patients.
BLA submission of rilparencel for accelerated approval is targeted for Q1 2028.
BLA accelerated approval and commercial launch of rilparencel are anticipated in 1H 2029.
Topline readout for the Phase 3 PROACT 1 confirmatory endpoint (composite time-to-event) is expected in 2H 2029.

The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.